BASEL, Switzerland I August 11, 2025 I FoRx Therapeutics, a clinical-stage biotechnology company developing precision anti-cancer therapeutics, today ...

SEOUL, South Korea I August 11, 2025 I AMI Pharm, a biotechnology company focused on aesthetic and therapeutic innovations, announced today that its lead ...

EAST HANOVER, NJ, USA I August 11, 2025 I Novartis today announced positive top-line results from its Phase III trials evaluating ianalumab (VAY736) in adults ...

HONG KONG, China I August 10, 2025 I Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in its multicenter, ...

STUTTGART, Germany I August 11, 2025 I Selecting the right target remains the most important decision to make in drug discovery and has to be seen in light of ...

YANTAI, China I August 8, 2025 I On August 8th, RemeGen Co., Ltd. (688331.SH/09995.HK) announces clearance of IND application by Food and Drug Administration ...

RIDGEFIELD, CT, USA and INGELHEIM, Germany I August 08, 2025 I Boehringer Ingelheim’s HERNEXEOS® (zongertinib tablets) has been approved by the U.S. Food and ...

PALI-2108 demonstrated to be safe and well tolerated with no serious adverse events (SAEs) Extended half-life and local bioactivation support convenient once-daily dosing in ulcer ...

Topline results from CATT1 Phase 3 trial expected in second half of 2026. HIGH POINT, NC, USA I August 07, 2025 I vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceuti ...

BERKELEY HEIGHTS, NJ, USA I August 07, 2025 I CorMedix Inc. (“CorMedix”) (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing ...

With this clearance, KTX-2001 becomes the second NSD2 inhibitor from K36 to advance into clinical development. This Phase 1 program will evaluate KTX-2001 both as a monotherapy and in combination with ...

ROCKVILLE, MD, USA I August 7, 2025 I REGENXBIO Inc. (Nasdaq: RGNX) today announced it will initiate a pivotal Phase IIb/III clinical trial for ...